Introduction
Recurrent chromosomal translocations and amplifications specifically target oncogenes involved in tumor development and maintenance. This underlines the importance of their characterization for understanding pathomechanisms of cancer development and uncovering rational targets for therapeutic intervention. Unlike tumor-suppressor genes and oncogenes targeted for genomic amplification, leukemic oncogenes activated by translocation are often developmental and, thus, rarely involved in solid tumors. 1 Gene amplification within chromosomal amplicons, manifesting as 'double minute' chromosomes or as 'homogeneously staining regions', occurs widely in solid tumors where it is believed to facilitate upregulated transcription of selected genes located therein. This phenomenon is less widespread in lymphoid and myeloid neoplasia where chromosome translocations affecting gene juxtapositions and fusions, respectively, predominate. 2 T-cell lymphomas represent about 12% of the total. 3 According to the cancer classification of the World Health Organization, T-cell lymphomas include anaplastic large-cell lymphoma (ALCL) and peripheral T-cell lymphoma, not otherwise specified (PTCL NOS). 4 ALCL is rareFrepresenting roughly 3% of all lymphomasFand the clinical course differs significantly between ALK-positive (ALK þ ) and ALK-negative (ALKÀ) ALCL patients. 3 The main chromosomal rearrangement in ALCL, t(2;5)(p23;q35), fuses NPM1 to ALK, which generates a constitutively active kinase-enhancing proliferation. 5, 6 Genes dysregulated by non-chromosomal mechanisms in ALCL cells include CCND3 and CDKN1B coding for cyclin D3 and p27, respectively, both key cell cycle regulators, highlighting the proliferative aspect of this disease. 7, 8 PTCL NOS is predominantly a nodal lymphoma and comprises up to 70% of T-cell lymphomas in western countries. 3 Cytogenetic abnormalities are common, although few recurrent aberrations have been described. 9 Cyclin-dependent kinases (CDKs) are key regulators of the cell cycle. Diverse CDKs are known, namely CDK1-10 in mammals. The G1-S phase transition of the cell cycle depends on CDK2, CDK4 and CDK6, which interact with D-type cyclins and phosphorylate retinoblastoma protein family members. 10 CDK inhibitors repress the activity of CDKs and encompass INK4 and KIP protein families, which include p27. 11 Here, we describe the analysis of an amplicon in the ALCLderived cell line SU-DHL-1 located at 7q22. This region is part of a larger amplicon described previously in ALCL cells. The reduced amplicon in SU-DHL-1 allows more focused analysis of genes located within this region. Accordingly, the aim of this study was the identification and characterization of candidate genes targeted by 7q22 amplification.
Materials and methods
Cell culture and patient samples 
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) analysis was performed on metaphases prepared from cell lines as described previously 12 using the following RP11 BAC clones obtained from the Sanger Institute, Cambridge, UK (www.genome.ucsc.edu): 315P14, 30D21, 371H19, 90H9, 232H24 and 124G15. Primary patient samples were analyzed by interphase FISH as described previously. 13 Briefly, FISH was performed in paraffinembedded material in a tissue microarray format. Cases showing a gain/amplification of the CDK6 locus were subsequently analyzed on whole paraffin-embedded tissue sections as well. The following RP11 BAC clones, used as spanning probes to detect the CDK6 locus, were purchased from the German Resource Centre for Genome Research, Berlin, Germany (www.rzpd.de): 467N23, 332M5 and 514K1. The centromeric probe cep7 (Abbott, Wiesbaden, Germany) as well as probes detecting the region slightly telomeric of the T-cell receptor genes TRG (7p14-15) and TRB (7q35) loci were used as reference probes.
14 For negative controls, CDK6 and cep7 probes were tested simultaneously in seven paraffin-embedded reactive lymph nodes as well as on cells from the cell lines MOLT-3 and HSB-2. The cell line SU-DHL-1 served as a positive control.
Reverse transcription-PCR
Reverse transcription (RT)-PCR analysis was performed as described previously. 15 Oligonucleotides are listed in Table 1 and were purchased from MWG, Martinsried, Germany. Quantitative real-time RT-PCR analysis was performed on an ABI 7500 SDS cycler, using commercial expression assays for CDK6 and TBP (Applied Biosystems, Darmstadt, Germany).
Immunocytology
Cytospin preparation and immunodetection were performed as described previously. 16 Antibody anti-CDK6 was obtained from Santa Cruz (Heidelberg, Germany).
Flow cytometry
Flow cytometry and cell cycle analysis were performed as described previously. 16 
Multiplex ligation-dependent probe amplification
Genomic copy-number determination was performed using a PCR-based multiplex ligation-dependent probe amplification (MLPA) kit, amplifying 40 cancer-related genes, including CDK6 (SALSA MS-MLPA kit ME001 tumor suppressor-1, MRCHolland, Amsterdam, The Netherlands). The mean amplification signal was set to 1.
Results and discussion
Classical cytogenetic analysis of ALCL cell line SU-DHL-1 revealed a homogeneously staining region on 7q ( Figure 1a ).
Using a BAC contig for FISH analysis, we determined both the size (9 Mb) and location (86-95 Mb) of the amplicon (Figure 1b) . Our results are consistent with genomic data provided by the Sanger Institute (www.sanger.ac.uk/cgi-bin/genetics/CGP/ 10kCGHviewer.cgi?dna ¼ SU-DHL-1), which show a sharp loss of heterozygosity peak and concomitant copy-number gains at B90 Mb. For precise copy-number determination at the 7q22 amplicon, we used a PCR-based MLPA assay, which simultaneously analyzed 40 genes, including CDK6 located within the amplicon at 92.1-92.3 Mb. Data indicated a 5-to 6-fold amplification of this gene in SU-DHL-1 (Figure 1c ). Additional data obtained by this assay revealed a threefold amplification of BRCA1 which is located at 17q21 (38.5 Mb), in keeping with Sanger Institute SNP-array data, which also show copy number increase at 37-50 Mb, i.e. covering 17q21, albeit unaccompanied by loss of heterozygosity. Furthermore, according to our MPLA analysis, the tumor-suppressor gene CHFR (at 12q24.3), which is reportedly hypermethylated in T-cell lymphoma, 17 seems to be deleted in SU-DHL-1 (Figure 1c ). CAAACTCTGAGCCCTGATTC  GAAACAGAACCTGTGACTCG  320  CDK6  NM_001259  CAAGACTTGACCACTTACTTGG  AAATATGCAGCCAACACTCCAG  321  DBF4  NM_006716  ACTGCAGAAACCACTTCACC  TTGTGCACCACTACCAACTC  488  GATAD1  NM_021167  ATACAAATCTGCTCCGGCTG  GCACTCTTCTCGCAATACTG  252  PPP1R9A  NM_017650  ATGACGAAGTTGACCCTGTG  TTATCAACTGGGACAACCTCG  375  SRI  NM_003130  CCGCTGTATGGTTACTTTGC  TGTAGTCGTCGAAGGTGATC  379 CDK6 in T-cell lymphoma S Nagel et al
Reconciling the 7q22 amplicon with the genomic map (UCSC Genome Bioinformatics) identified six amplified genes plausibly involved in cancer: DBF4, SRI, AKAP9, GATAD1, CDK6 and PPP1R9A. Comparative expression of these candidates was analyzed by RT-PCR in SU-DHL-1 and SR-786, an ALCL cell line lacking any amplification at 7q22 (data not shown). All six genes were expressed in SU-DHL-1 and SR-786 cells, except PPP1R9A, which remained silent in both cell lines (Figure 2a) . The PCR product of CDK6 appeared slightly stronger in SU-DHL-1, indicating overexpression of that gene. To analyze CDK6 expression levels, we performed semiquantitative RT-PCR analysis, using serially diluted cDNAs (Figure 2b ). The amounts of PCR products from SR-786 decreased significantly in contrast to those of SU-DHL-1, supporting higher CDK6 expression in this cell line. Recently, a more extended amplification located at 7q21-31 was identified in ALCL cell line L-82. 18 Resembling SU-DHL-1, MLPA analysis of L-82 demonstrated amplification of CDK6 (threefold), BRCA1 (twofold) and deletion of CHFR (data not shown). Although overexpression of HGF and c-MET has been described as a consequence of this amplification, expression of CDK6 has not been analyzed in this cell line. 18 We performed quantitative expression analysis of CDK6 by real-time PCR in SU-DHL-1, L-82 and five additional ALCL cell lines, lacking 7q22 amplification (Figure 2c ). These data demonstrated high-level CDK6 expression in SU-DHL-1 (10-fold) and L-82 (fivefold) in comparison to ALCL control cell lines, corresponding to their respective genomic copy numbers. To analyze CDK6 expression at the protein level, we performed immunocytology in both SU-DHL-1 and SR-786 cells (Figure 2d ). Positive immunostaining is visible in nucleus and cytoplasm, in accordance with the published cellular distribution of CDK6 protein. 19 Importantly, staining appeared significantly brighter in SU-DHL-1 cells, confirming overexpression of CDK6 at the protein level.
In T-cells, CDK6 is a major factor driving proliferation. 20 Both CDK6 and cyclin D3 are prominent regulators in this cell type, conducting the cell cycle through G1 phase. 20, 21 Furthermore, overexpression of both genes has been described to promote malignant transformation. 22 Rapamycin has been shown to inhibit the AKT pathway responsible for degradation of the CDK inhibitor p27 and to downregulate cyclin D3 levels in ALCL and T cells, respectively. 8, 23 Consequently, SU-DHL-1, SR-786 and L-82 cells were treated with two different concentrations of rapamycin, specifying cell growth as end point. Data indicated an inverse correlation of rapamycin sensitivity and CDK6 expression levels (Figure 3) . Furthermore, cell cycle analysis of rapamycin-treated cells demonstrated in SR-786 a cell cycle arrest at G1 phase in contrast to SU-DHL-1, where no effect was detected ( Table 2 ). These data suggest that SU-DHL-1 cells are better able to proliferate with both reduced cyclin D3 and elevated p27 levels, respectively.
To study CDK6 amplification in primary T-cell lymphoma samples we performed interphase FISH analysis on paraffinembedded material in a tissue microarray format.
First, we established the experimental conditions in cell line samples, using SU-DHL-1 as positive, and MOLT-3 as negative CDK6 in T-cell lymphoma S Nagel et al controls, respectively (Figure 4a ). Hybridizing the CDK6 probes in SU-DHL-1 cells, the results confirmed exclusive and unequivocal amplification in contrast to the centromeric chromosome 7 probe (cep7), showing wild-type configuration. Next we analyzed 64 ALCL samples of which 30 were ALK þ and 34 ALKÀ. Of these, only one sample (ALKÀ, case 11) showed a gain of CDK6 (Figure 4b ). In addition to cep7, probe 7q35 detecting the TRB locus also indicated gain of material in contrast to probe 7p14-15 (hybridizing slightly telomeric of the TRG locus), showing wild-type configuration. These results from ALCL patient samples indicated a low frequency (B1%) of CDK6 amplification potentially involved in a more extended amplicon at 7q.
In contrast to ALCL, PTCL NOS samples have been shown to possess gains at 7q. 9 To test if these gains include CDK6, we subsequently examined patient samples of this T-cell lymphoma subtype for CDK6 amplification in the same way. In 2/22 (9%) PTCL NOS samples, gain/amplification of the CDK6 locus was detected as exemplified by Figure 4c . Out of the cases hybridized successfully with the CDK6 and cep7 probes, 20 PTCL NOS cases were co-hybridized with probes for CDK6 and 7p14-15. This hybridization strategy led to three additional PTCL NOS cases revealing gain of CDK6. Assuming that a larger part of the 7q arm was affected in these cases, we applied a FISH assay, detecting both the CDK6 locus and the chromosomal region 7q35 (TRB), which confirmed our hypothesis (Figure 4d ). Taken together, we identified 5/22 (23%) PTCL NOS cases and 1/44 (2%) ALKÀ ALCL cases, demonstrating gain/amplification at the CDK6 locus. These results indicate that CDK6 gain/ amplification seldom occurs in ALCL but rather more frequently in PTCL NOS, corresponding to previous reports of 7q gains in PTCL exceeding those in ALCL samples. 9 Overexpression of CDK6 has been described in both T-cell leukemia and lymphoma, albeit without gene amplification, 24, 25 indicating additional mechanisms underlying aberrant activation. Furthermore, in Hodgkin lymphoma, CDK6 overexpression occurs in concert with other cell cycle checkpoint-associated genes 26 and in splenic marginal zone lymphoma, the CDK6 locus is juxtaposed with the immunoglobulin kappa locus via t(2;7)(p12;q22) driving overexpression. 27 Similarly, CDK6 overexpression in chronic lymphocytic leukemia occurs rarely by juxtaposition with IGH via formation of t(7;14)(q21;q32), 28 while juxtaposition with TLX3 via t(5;7)(q35;q21) in T-cell leukemia has been reported. 29 These data, together with reports of CDK6 overexpression in solid tumors, including glioblastoma, 30 Figure 3 Anaplastic large-cell lymphoma (ALCL) cell lines SU-DHL-1, SR-786 and L-82 were treated with two concentrations of the AKT pathway inhibitor rapamycin (50 and 500 ng ml À1 for 18 h). In contrast to SU-DHL-1, the number of viable SR-786 cells was decreased. This experiment was performed twice with similar results.
Table 2
Cell cycle analysis of rapamycin-treated cells CDK6 in T-cell lymphoma S Nagel et al gastric cancer 31 and squamous cell carcinoma 32 indicate a wide role for CDK6 in cancerogenesis.
The fusion protein NPM-ALK activates the AKT pathway that is involved in degradation of the CDK inhibitor p27, subsequently expressed at low levels in ALCL cells. 8 Forced overexpression of CDKN1B (coding for p27), results in cell cycle arrest of SU-DHL-1 cells; however, in unexpected contrast to KARPAS-299 cells. 33 Furthermore, overexpression of cyclin D3 has been described in ALCL cells, 7 supporting the pathogenic potential of dysregulated CDKs in this tumor type. Underpinning the significance of these factors in T-cell lymphoma, treatment with HSP90 inhibitor forcing degradation of CDK6 and other cell cycle regulators has shown promise in treatment of T-cell lymphoma. 34 In conclusion, 7q22 amplification combined with CDK6 overexpression highlights this gene as a key regulator of cell cycle progression and the pathogenic significance of CDK dysregulation in T-cell lymphoma in general. CDK6 is one of a minority of oncogenes chromosomally rearranged in leukemialymphoma, which is also dysregulated in solid tumors. Hence, ALCL cell lines SU-DHL-1 and L-82 represent unique tools with which to investigate both the pathogenic role of CDK6 and its potential to serve as a therapeutic target in T-cell lymphoma and, more generally, in other types of cancers.
